Scribe Therapeutics
As seen on the 24/7 Wall St. homepage on July 10, 2026.
Scribe Therapeutics
SCTX · Nasdaq
Scribe Therapeutics amends S-1 ahead of Nasdaq IPO debut under SCTX
CRISPR gene-editing biotech Scribe Therapeutics updated its IPO registration with Nasdaq backing, enlisting Goldman Sachs, Leerink Partners, Guggenheim Securities, and Wells Fargo as lead underwriters for the push toward public markets.
Mentioned: SCTX